Carl L. Gordon - 28 Sep 2026 Form 4 Insider Report for ADARx Pharmaceuticals, Inc. (ADRX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ADRX
Reported as of: 28 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Sep 2026, 17:25:39 UTC
Prior SEC filing: 24 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon

Key filing fact

Carl L. Gordon filed Form 4 for ADARx Pharmaceuticals, Inc. (ADRX) on 30 Sep 2026.

Key facts

This page summarizes Carl L. Gordon's Form 4 filing for ADARx Pharmaceuticals, Inc. (ADRX).
19 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 30 Sep 2026, 17:25.

Change

Previous filing in this sequence was filed on 24 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001282930 Primary reporting owner

GORDON CARL L

Relationship: Director, 10%+ Owner
Address: C/O ADARX PHARMACEUTICALS, INC., 5871 OBERLIN DRIVE, SUITE 200, SAN DIEGO
Signature: /s/ Carl L. Gordon
Signature date: 30 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +10,690,530
Change %
Price
Shares after: 10,690,530
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F3, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,000,962
Change %: +19%
Price
Shares after: 12,691,492
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F3, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +769,601
Change %: +6.1%
Price
Shares after: 13,461,093
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F3, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +564,187
Change %: +4.2%
Price
Shares after: 14,025,280
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F3, F6

ADRX transaction

Common Stock

Purchase

Transaction value
Shares: +300,249
Change %: +2.1%
Price: $17.00^*
Shares after: 14,325,529
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F2, F3, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +7,127,019
Change %
Price
Shares after: 7,127,019
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F4, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +1,333,975
Change %: +19%
Price
Shares after: 8,460,994
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F4, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +513,067
Change %: +6.1%
Price
Shares after: 8,974,061
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F4, F6

ADRX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +256,448
Change %: +2.9%
Price
Shares after: 9,230,509
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F1, F4, F6

ADRX transaction

Common Stock

Purchase

Transaction value
Shares: +61,516
Change %: +0.67%
Price: $17.00^*
Shares after: 9,292,025
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F2, F4, F6

ADRX transaction

Common Stock

Purchase

Transaction value
Shares: +588,235
Change %
Price: $17.00^*
Shares after: 588,235
Date: 28 Sep 2026
Ownership: See footnotes
Footnotes: F2, F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADRX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -10,690,530
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 10,690,530
Exercise price
Footnotes: F1, F3, F6

ADRX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -2,000,962
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 2,000,962
Exercise price
Footnotes: F1, F3, F6

ADRX transaction Derivative

Series B-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -769,601
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 769,601
Exercise price
Footnotes: F1, F3, F6

ADRX transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares: -564,187
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 564,187
Exercise price
Footnotes: F1, F3, F6

ADRX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -7,127,019
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 7,127,019
Exercise price
Footnotes: F1, F4, F6

ADRX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,333,975
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 1,333,975
Exercise price
Footnotes: F1, F4, F6

ADRX transaction Derivative

Series B-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -513,067
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 513,067
Exercise price
Footnotes: F1, F4, F6

ADRX transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares: -256,448
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 28 Sep 2026
Ownership: See footnotes
Underlying class: Common Stock
Underlying amount: 256,448
Exercise price
Footnotes: F1, F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.

Footnote F2

Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.

Footnote F3

These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.

Footnote F4

These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advisors Israel") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of the Reporting Person, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.

Footnote F5

These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.

Footnote F6

Each of the Reporting Person, OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.